--- title: "Gilead inks Manta pact to dive deeper into cancer patient aid" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/280338368.md" description: "Gilead Sciences has partnered with Manta Cares to enhance cancer patient support by distributing customized navigation tools for lung and breast cancer care. Manta's digital platform, which helps patients track treatment options and manage symptoms, will be utilized in this collaboration. Gilead's involvement includes rolling out a planner for metastatic non-small cell lung cancer and supporting ongoing research into the platform's real-world use. This partnership coincides with Gilead's upcoming FDA filings for Trodelvy in additional breast cancer types and updates on phase 3 trials for lung and endometrial cancers." datetime: "2026-03-24T14:55:22.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280338368.md) - [en](https://longbridge.com/en/news/280338368.md) - [zh-HK](https://longbridge.com/zh-HK/news/280338368.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/280338368.md) | [English](https://longbridge.com/en/news/280338368.md) # Gilead inks Manta pact to dive deeper into cancer patient aid Gilead Sciences has partnered with digital health company Manta Cares to get tools for navigating lung and breast cancer care pathways to patients. Manta launched a planner in 2021 to help cancer patients track treatment options, monitor symptoms and otherwise stay on top of the admin associated with oncology care. Having originally created a paper planner for all cancers, Manta went on to set up a digital platform and tailor its tools to different tumor types. The company said last year that it works with three of the top 15 drugmakers. Gilead’s involvement will support the nationwide distribution of customized navigation tools for lung and breast cancers, two tumor types targeted by the pharma’s antibody-drug conjugate Trodelvy. The ADC, which generated (PDF) sales of $1.4 billion last year, is approved in two types of breast cancer and in development in lung cancer. The drugmaker will specifically help roll out across the U.S. Manta’s customized planner for metastatic non-small cell lung cancer, which the digital health company developed with input from the nonprofit LUNGevity Foundation. The collaboration will also encompass real-world pilot programs, community outreach and ongoing research, according to the companies’ joint announcement. Elsewhere, as part of the team-up, Gilead is lending its support to ongoing studies by independent investigators into how patients and providers use the Manta platform in real-world settings. So far, the research has found that patients use the planners to organize questions, track medications and appointments, and structure their conversations with care teams, all of which helps them feel “more confident and prepared,” per the release. Gilead has played a role in some previous assessments of Manta’s tools. The pharma was involved in recruiting patients in a study of Manta’s cancer care web app that began in 2024, and it also provided funding for a study of the company’s digital navigation platform that reported results last year. The latest news of Gilead’s work with Manta arrives at an important moment for the drugmaker’s cancer plans. Gilead has said (PDF) that it expects the FDA to rule on filings for approval of Trodelvy in two more types of breast cancer in the second half of the year, and the company plans to provide updates on phase 3 trials of the ADC in non-small cell lung cancer and endometrial cancer over the same time frame. ### 相關股票 - [Direxion S&P Biotech Bull 3X (LABU.US)](https://longbridge.com/zh-HK/quote/LABU.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md) - [Gilead Sciences (GILD.US)](https://longbridge.com/zh-HK/quote/GILD.US.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md) - [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md) ## 相關資訊與研究 - [Gilead extends Arcellx tender offer expiration date](https://longbridge.com/zh-HK/news/281422486.md) - [BUZZ-Caribou rises on FDA's regenerative medicine advanced therapy tag for blood cancer therapy](https://longbridge.com/zh-HK/news/281186075.md) - [ABION Presents Preclinical Data at AACR Showing IFN-β Antibody Fusion ABN202 Outperforms TROP2-Targeting ADCs](https://longbridge.com/zh-HK/news/281822825.md) - [MSD secures EC clearance for Keytruda combination therapy for ovarian cancer](https://longbridge.com/zh-HK/news/281737265.md) - [Vertex Pharmaceuticals Says US FDA Approves Label Expansion for Alyftrek, Trikafta](https://longbridge.com/zh-HK/news/281365753.md)